Ketamine: Stimulating antidepressant treatment?

Gin S. Malhi; Yulisha Byrow; Frederick Cassidy; Andrea Cipriani; Koen Demyttenaere; Mark A. Frye; Michael Gitlin; Sidney H. Kennedy; Terence A. Ketter; Raymond W. Lam; Rupert McShane; Alex J. Mitchell; Michael J. Ostacher; Sakina J. Rizvi; Michael E. Thase; Mauricio Tohen

doi:10.1192/bjpo.bp.116.002923

Ketamine: Stimulating antidepressant treatment?

Gin S. Malhi, Yulisha Byrow, Frederick Cassidy, Andrea Cipriani, Koen Demyttenaere, Mark A. Frye, Michael Gitlin, Sidney H. Kennedy, Terence A. Ketter, Raymond W. Lam, Rupert McShane, Alex J. Mitchell, Michael J. Ostacher, Sakina J. Rizvi, Michael E. Thase, Mauricio Tohen

Psychiatry and Psychology

Research output: Contribution to journal › Review article › peer-review

17 Scopus citations

Abstract

The appeal of ketamine - in promptly ameliorating depressive symptoms even in those with non-response - has led to a dramatic increase in its off-label use. Initial promising results await robust corroboration and key questions remain, particularly concerning its long-term administration. It is, therefore, timely to review the opinions of mood disorder experts worldwide pertaining to ketamine's potential as an option for treating depression and provide a synthesis of perspectives - derived from evidence and clinical experience - and to consider strategies for future investigations.

Original language	English (US)
Pages (from-to)	E5-E9
Journal	BJPsych Open
Volume	2
Issue number	3
DOIs	https://doi.org/10.1192/bjpo.bp.116.002923
State	Published - 2016

ASJC Scopus subject areas

Psychiatry and Mental health

Access to Document

10.1192/bjpo.bp.116.002923

Cite this

@article{dc7cf4c4b87141328cdb9963e0d35d5c,

title = "Ketamine: Stimulating antidepressant treatment?",

abstract = "The appeal of ketamine - in promptly ameliorating depressive symptoms even in those with non-response - has led to a dramatic increase in its off-label use. Initial promising results await robust corroboration and key questions remain, particularly concerning its long-term administration. It is, therefore, timely to review the opinions of mood disorder experts worldwide pertaining to ketamine's potential as an option for treating depression and provide a synthesis of perspectives - derived from evidence and clinical experience - and to consider strategies for future investigations.",

author = "Malhi, {Gin S.} and Yulisha Byrow and Frederick Cassidy and Andrea Cipriani and Koen Demyttenaere and Frye, {Mark A.} and Michael Gitlin and Kennedy, {Sidney H.} and Ketter, {Terence A.} and Lam, {Raymond W.} and Rupert McShane and Mitchell, {Alex J.} and Ostacher, {Michael J.} and Rizvi, {Sakina J.} and Thase, {Michael E.} and Mauricio Tohen",

note = "Publisher Copyright: {\textcopyright} The Royal College of Psychiatrists 2016.",

year = "2016",

doi = "10.1192/bjpo.bp.116.002923",

language = "English (US)",

volume = "2",

pages = "E5--E9",

journal = "BJPsych Open",

issn = "2056-4724",

publisher = "Cambridge University Press",

number = "3",

}

TY - JOUR

T1 - Ketamine

T2 - Stimulating antidepressant treatment?

AU - Malhi, Gin S.

AU - Byrow, Yulisha

AU - Cassidy, Frederick

AU - Cipriani, Andrea

AU - Demyttenaere, Koen

AU - Frye, Mark A.

AU - Gitlin, Michael

AU - Kennedy, Sidney H.

AU - Ketter, Terence A.

AU - Lam, Raymond W.

AU - McShane, Rupert

AU - Mitchell, Alex J.

AU - Ostacher, Michael J.

AU - Rizvi, Sakina J.

AU - Thase, Michael E.

AU - Tohen, Mauricio

PY - 2016

Y1 - 2016

N2 - The appeal of ketamine - in promptly ameliorating depressive symptoms even in those with non-response - has led to a dramatic increase in its off-label use. Initial promising results await robust corroboration and key questions remain, particularly concerning its long-term administration. It is, therefore, timely to review the opinions of mood disorder experts worldwide pertaining to ketamine's potential as an option for treating depression and provide a synthesis of perspectives - derived from evidence and clinical experience - and to consider strategies for future investigations.

AB - The appeal of ketamine - in promptly ameliorating depressive symptoms even in those with non-response - has led to a dramatic increase in its off-label use. Initial promising results await robust corroboration and key questions remain, particularly concerning its long-term administration. It is, therefore, timely to review the opinions of mood disorder experts worldwide pertaining to ketamine's potential as an option for treating depression and provide a synthesis of perspectives - derived from evidence and clinical experience - and to consider strategies for future investigations.

UR - http://www.scopus.com/inward/record.url?scp=85017096136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017096136&partnerID=8YFLogxK

U2 - 10.1192/bjpo.bp.116.002923

DO - 10.1192/bjpo.bp.116.002923

M3 - Review article

AN - SCOPUS:85017096136

SN - 2056-4724

VL - 2

SP - E5-E9

JO - BJPsych Open

JF - BJPsych Open

IS - 3

ER -

Ketamine: Stimulating antidepressant treatment?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this